Elimination of wild-type P53 mRNA in glioblastomas showing heterozygous mutations of P53

British Journal of Cancer

Volumn 98, Issue 8, 2008, Pages 1431-1433

  Szybka, M ^a   Zawlik, I ^a   Kulczycka, D ^a   Golanska, E ^a   Jesien, E ^a   Kupnicka, D ^a   Stawski, R ^a   Piaskowski, S ^a   Bieniek, E ^a   Zakrzewska, M ^a   Kordek, R ^a   Liberski, P P ^a   Rieske, P ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Glioblastoma; Methylation; mRNA; P53

Indexed keywords

MESSENGER RNA; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GLIOBLASTOMA; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; MALE; METHYLATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GENES, P53; GLIOBLASTOMA; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 42149144027     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604258     Document Type: Article

References (11)

1. Amatya VJ, Naumann U, Weller M, Ohgaki H (2005) TP53 promoter methylation in human gliomas. Acta Neuropathol (Berl) 110: 178-184, doi: 10.1007/s00401-005-1041-5
2. Chan WM, Siu WY, Lau A, Poon RY (2004) How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol 24: 3536-3551
3. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ (1993) Gain of function mutations in p53. Nat Genet 4: 42-46, doi: 10.1038/ng0593-42
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO Classification of tumors of the central nervous system. Acta Neuropathol (Berl) 114: 97-109
5. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hosteller R, Cleary K, Signer SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weslon A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-707, doi: 10.1038/342705a0
6. Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL, Koeffler HP (1994) Transactivational and DNA-binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 9: 1899-1906
7. Sherr C (2004) Principles of tumor suppression. Cell 116: 235-246, doi: 10.1016/S0092-8674(03)01075-4
8. Sun Y, Dong Z, Nakamura K, Colburn NH (1993) Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma. FASEB J 7: 944-950
9. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH, Agami R (2006) A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumours. Cell 124: 1169-1181, doi: 10.1016/j.cell.2006.02.037
10. Watanabe T, Katayama Y, Yoshino A, Yachi K, Ohta T, Ogino A, Komine C, Fukushima T (2007) Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol 17: 5-10, doi: 10.1111/j.1750-3639.2006.00030.x
11. Zakrzewska M, Wojcik I, Zakrzewski K, Polis L, Grajkowska W, Roszkowski M, Augelli BJ, Liberski PP, Rieske P (2005) Mutational analysis of hSNF5/INI1 and TP53 genes in choroid plexus carcinomas. Cancer Genet Cytogenet 156: 179-182, doi:10.1016/j.cancergencyto.2004.05.002